Financial Tear Sheet Corporate Profile Primary IR Contact Stock
... SPNC develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the Guy Childs cardiovascular system. The Company’s products are available in over Vice President 65 countries and are used to treat arterial blockages in the heart and Phone: 719-633-83 ...
... SPNC develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the Guy Childs cardiovascular system. The Company’s products are available in over Vice President 65 countries and are used to treat arterial blockages in the heart and Phone: 719-633-83 ...
The Safety and Clinical Outcome in Unprotected Intervention of Left
... recommended by the American College of Cardiology / American Heart Association (ACC/AHA) guidelines should be considered revised from Class III to be Class II a. The revolution of PCI by DES and intravascular ultrasound have been more recognized to improve on positive procedure outcomes. Study Limit ...
... recommended by the American College of Cardiology / American Heart Association (ACC/AHA) guidelines should be considered revised from Class III to be Class II a. The revolution of PCI by DES and intravascular ultrasound have been more recognized to improve on positive procedure outcomes. Study Limit ...
Percutaneous Transluminal Coronary Angioplasty in a Patient with
... coronary anatomy and the degree of luminal obstruction of the coronary arteries. It is most commonly used to determine the presence and extent of obstructive coronary artery disease and to assess the feasibility and appropriateness of various forms of therapy, such as revascularization by percutaneo ...
... coronary anatomy and the degree of luminal obstruction of the coronary arteries. It is most commonly used to determine the presence and extent of obstructive coronary artery disease and to assess the feasibility and appropriateness of various forms of therapy, such as revascularization by percutaneo ...
BioMatrix Clinical Trial Backgrounder
... e-BioMatrix The e-BioMatrix Registry, initiated in March 2008, is a prospective, multi-center, observational registry to assess the outcomes of over 6,000 “real-world” patients across 77 European study sites over a five-year period. Enrolment in the Post-Marketing Surveillance (PMS) arm was complete ...
... e-BioMatrix The e-BioMatrix Registry, initiated in March 2008, is a prospective, multi-center, observational registry to assess the outcomes of over 6,000 “real-world” patients across 77 European study sites over a five-year period. Enrolment in the Post-Marketing Surveillance (PMS) arm was complete ...
Myocardial bridge – diagnosis and treatment in a congenital anomaly
... incidental finding during angiography and no signs of ischemia are present, patients usually do not need any treatment. Patients from group B with evidence of ischemia during exercise stress test or any imaging technique and with signs of ischemia are treated pharmacologically with beta blockers (BB ...
... incidental finding during angiography and no signs of ischemia are present, patients usually do not need any treatment. Patients from group B with evidence of ischemia during exercise stress test or any imaging technique and with signs of ischemia are treated pharmacologically with beta blockers (BB ...
Chronic stable angina
... Potential for Dysrhythmias • Dysrhythmias are the leading cause of death in most patients with MI who die before they can be hospitalized. • Interventions include: • Identify the dysrhythmias. • Assess hemodynamic status. • Evaluate for discomfort. ...
... Potential for Dysrhythmias • Dysrhythmias are the leading cause of death in most patients with MI who die before they can be hospitalized. • Interventions include: • Identify the dysrhythmias. • Assess hemodynamic status. • Evaluate for discomfort. ...
Coronary Artery Bypass Graft (CABG)
... 5. 2 or 3-vessel disease if one of the vessels involved is the proximal LAD. Studies have proven improved survival in left main disease and 3-vessel disease with impaired LV function. Most frequent complications from CABG surgery include: Graft closures remain a limiting factor to the success of CAB ...
... 5. 2 or 3-vessel disease if one of the vessels involved is the proximal LAD. Studies have proven improved survival in left main disease and 3-vessel disease with impaired LV function. Most frequent complications from CABG surgery include: Graft closures remain a limiting factor to the success of CAB ...
Biofreedom Backgrounder
... symptomatic ischemic heart disease, equally randomized into three groups: those treated with BioFreedom SD; those treated with BioFreedom LD; and those treated with Taxus Liberté. All patients have been scheduled for clinical follow-up at 1 month, 4 months, and annually through to 5 years. The first ...
... symptomatic ischemic heart disease, equally randomized into three groups: those treated with BioFreedom SD; those treated with BioFreedom LD; and those treated with Taxus Liberté. All patients have been scheduled for clinical follow-up at 1 month, 4 months, and annually through to 5 years. The first ...
coronary artery calcification and its relation to systolic function
... coronary artery calcification and its relation to LV function estimated by MsCT in chronic coronary artery disease. Patients and Methods: Out of 758 persons who were referred to 64 slices MSCT, the total of 156 (age 50 to 69 years, 64% males) in sinus rhythm with chronic coronary artery disease were ...
... coronary artery calcification and its relation to LV function estimated by MsCT in chronic coronary artery disease. Patients and Methods: Out of 758 persons who were referred to 64 slices MSCT, the total of 156 (age 50 to 69 years, 64% males) in sinus rhythm with chronic coronary artery disease were ...
Restenosis - Repeat Narrowing of a Coronary Artery
... uses a radioactive source that is delivered by a coronary artery catheter inside the narrowed artery for a short period of time (about 10 minutes). The source is removed and does not stay in the body. Because the short period of radiation inhibits long-term tissue growth in the treated vessel, it su ...
... uses a radioactive source that is delivered by a coronary artery catheter inside the narrowed artery for a short period of time (about 10 minutes). The source is removed and does not stay in the body. Because the short period of radiation inhibits long-term tissue growth in the treated vessel, it su ...
National Imaging Associates, Inc. Clinical guidelines HEART
... Heart Catheterization is an invasive angiographic procedure used to evaluate the presence and extent of coronary artery disease (CAD) as well as ventricular and valvular function. It can be used to perform various tests, including angiography, intravascular ultrasonography, and measurement of cardia ...
... Heart Catheterization is an invasive angiographic procedure used to evaluate the presence and extent of coronary artery disease (CAD) as well as ventricular and valvular function. It can be used to perform various tests, including angiography, intravascular ultrasonography, and measurement of cardia ...
... also measured in aU cases. In patients treated with Palmaz stent for tatrogenic arterial dissection an average of 2.1 stents ware used (most frequent lesion was longer than 4 cm). In longer dissections we have used Memotherm stent External mechanical compression (on average 30-40 min) was successful ...
Instructions to patients scheduled for coronary - Hoito
... In balloon angioplasty, a balloon catheter is inserted into the narrowed location. The balloon at the end of the catheter is filled with water. This causes the balloon to inflate, forcing the narrowing in the vessel to expand. During the procedure, a stent (a metal mesh) is often placed in the narro ...
... In balloon angioplasty, a balloon catheter is inserted into the narrowed location. The balloon at the end of the catheter is filled with water. This causes the balloon to inflate, forcing the narrowing in the vessel to expand. During the procedure, a stent (a metal mesh) is often placed in the narro ...
ST - segment Elevation Myocardial Infarction complicating an
... A 48 occlusion LAD h coronary and dissection arteriography: ...
... A 48 occlusion LAD h coronary and dissection arteriography: ...
HeartFlow Secures De Novo Clearance from the US Food and Drug
... damaged, often because of the build up of plaque in the vessel walls. The plaque – or lesions – can cut off vital blood flow to the heart, causing chest pain, heart attacks and death. Coronary artery disease affects an estimated 16.3 million adults and is one of the most costly medical conditions to ...
... damaged, often because of the build up of plaque in the vessel walls. The plaque – or lesions – can cut off vital blood flow to the heart, causing chest pain, heart attacks and death. Coronary artery disease affects an estimated 16.3 million adults and is one of the most costly medical conditions to ...
Glossary - HKEXnews
... tissue without open-heart surgery. In PTCA, the coronary arteries are widened with the help of a balloon ...
... tissue without open-heart surgery. In PTCA, the coronary arteries are widened with the help of a balloon ...
What is Coronary Artery Disease?
... to treat CAD. Statins, beta blockers, ace inhibitors, calcium channel blockers, and nitrates are very commonly used. Ranexa is another agent that may be needed to treat patients with persistent or chronic chest pain. Interventional therapy includes percutaneous coronary intervention (PCI) or coronar ...
... to treat CAD. Statins, beta blockers, ace inhibitors, calcium channel blockers, and nitrates are very commonly used. Ranexa is another agent that may be needed to treat patients with persistent or chronic chest pain. Interventional therapy includes percutaneous coronary intervention (PCI) or coronar ...
1 - Broad`s MBA
... PolyNovo Biomaterials Pty Ltd has signed a partnering and licensing agreement with Medtronic, Inc. for the development, supply and commercialization of PolyNovo's NovoSorb(TM) for the prevention and treatment of cardiac and vascular disease, focusing on next generation stent products. Biodegradable ...
... PolyNovo Biomaterials Pty Ltd has signed a partnering and licensing agreement with Medtronic, Inc. for the development, supply and commercialization of PolyNovo's NovoSorb(TM) for the prevention and treatment of cardiac and vascular disease, focusing on next generation stent products. Biodegradable ...
cardiovascular disease fact sheet.pub
... If a cardiologist has found coronary artery blockages during a catheterization, they may recommend coronary artery bypass surgery to protect the heart muscle from these threatening blockages. ...
... If a cardiologist has found coronary artery blockages during a catheterization, they may recommend coronary artery bypass surgery to protect the heart muscle from these threatening blockages. ...
Coronary Anomalies & Staged Revascularization
... • Retrospective study analyzing 253 angiograms • Single complex plaques were identified in 153 ...
... • Retrospective study analyzing 253 angiograms • Single complex plaques were identified in 153 ...
Metabolic syndrome and prognosis of ischemic mitral insufficiency
... Coronary artery disease (CAD) is graded in relation to the number of vessels wich were significant as stenostic (one, two, three, four and multi-vessel CAD). Patients underwent surgical (coronary artery baypass grafting (CABG)) and percutaneous revascularization (percutaneus coronary intervention (P ...
... Coronary artery disease (CAD) is graded in relation to the number of vessels wich were significant as stenostic (one, two, three, four and multi-vessel CAD). Patients underwent surgical (coronary artery baypass grafting (CABG)) and percutaneous revascularization (percutaneus coronary intervention (P ...
Pulmonary Hemorrhage after Percutaneous Coronary Intervention
... high-dose bolus regimen, tirofiban may be considered useful in the management of patients with STEMI.1,2 Although tirofiban is not currently approved for use in STEMI patients or as adjunctive therapy in patients undergoing PCI, we used tirofiban in this case. Tirofiban hydrochloride infusion (25 mu ...
... high-dose bolus regimen, tirofiban may be considered useful in the management of patients with STEMI.1,2 Although tirofiban is not currently approved for use in STEMI patients or as adjunctive therapy in patients undergoing PCI, we used tirofiban in this case. Tirofiban hydrochloride infusion (25 mu ...
שקופית 1
... • Unloading of the left ventricle. • Increase of coronary and end-organ perfusion. • Low anticoagulation required; Anti Clotting time - 200 sec. • Reduction in myocardial workload. • Low complication rate. • Reduces risk of hemodynamic deterioration during ...
... • Unloading of the left ventricle. • Increase of coronary and end-organ perfusion. • Low anticoagulation required; Anti Clotting time - 200 sec. • Reduction in myocardial workload. • Low complication rate. • Reduces risk of hemodynamic deterioration during ...